title: Common therapeutic targets in cardiometabolic disease.
abstract: The interactions between cardiovascular disease (CVD) and insulin resistance syndromes suggest the possibility of joint targets for cardiometabolic research. The best drugs would go beyond minimizing adverse effects and have protective actions against both metabolic disease and CVD. In this perspective, we will outline a few examples in which a deep mechanistic understanding of the many cellular pathways that contribute to type 2 diabetes and CVD, regardless of cell type, have resulted in common upstream pathogenic pathways that can be therapeutically targeted.
authors.affiliation: Department of Medicine, Department of Pathology and Cell Biology, and Department of Physiology, Columbia University, New York, NY 10032-3725, USA.
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Fredman
authors.affiliation: Department of Medicine, Department of Pathology and Cell Biology, and Department of Physiology, Columbia University, New York, NY 10032-3725, USA.
authors.forename: Lale
authors.initials: L
authors.lastname: Ozcan
authors.affiliation: Department of Medicine, Department of Pathology and Cell Biology, and Department of Physiology, Columbia University, New York, NY 10032-3725, USA. iat1@columbia.edu.
authors.forename: Ira
authors.initials: I
authors.lastname: Tabas
mesh_terms: D000818:Animals; D020013:Calcium Signaling; D002318:Cardiovascular Diseases / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D059865:Endoplasmic Reticulum Stress; D006801:Humans; D007249:Inflammation / Q000473:pathology; D058990:Molecular Targeted Therapy